Radioimmunotherapy of intracerebral human glioma xenografts with super(131)I-labeled F(ab') sub(2) fragments of monoclonal antibody Mel-14

The administration of radiolabeled monoclonal antibodies to improve the treatment of malignant gliomas is dependent upon achieving effective tumor radiation dose while sparing normal tissues. We have evaluated the efficacy of super(131)I-labeled F(ab') sub(2) fragment of monoclonal antibody Mel...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 50; no. 6; pp. 1822 - 1827
Main Authors Colapinto, E V, Zalutsky, M R, Archer, GE, Noska, MA, Friedman, H S, Carrel, S, Bigner, D D
Format Journal Article
LanguageEnglish
Published 01.01.1990
Online AccessGet full text

Cover

More Information
Summary:The administration of radiolabeled monoclonal antibodies to improve the treatment of malignant gliomas is dependent upon achieving effective tumor radiation dose while sparing normal tissues. We have evaluated the efficacy of super(131)I-labeled F(ab') sub(2) fragment of monoclonal antibody Mel-14, an IgG2a reactive with the chondroitin sulfate proteoglycan antigen of gliomas, melanomas, and other neoplasms, in prolonging survival of athymic mice transplanted intracerebrally with D-54 MG human glioma xenografts. The results of this study suggest that radiolabeled Mel-14 F(ab') sub(2) be evaluated as an agent for radioimmunotherapy trials.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Feature-1
ISSN:0008-5472